Summary
DexCom, Inc. (DXCM) reported its financial and operational results for the quarter ended March 31, 2014. The company saw a significant increase in product revenues, driven by the G4 PLATINUM continuous glucose monitoring (CGM) system, which was commercially launched in October 2012. This growth, combined with a favorable product mix leaning towards the higher-margin G4 PLATINUM, led to a substantial increase in gross profit year-over-year. Despite revenue growth, the company continues to invest heavily in research and development, as well as selling, general, and administrative expenses, leading to a net loss for the quarter. Significant increases in R&D were driven by equity-related expenses, headcount, and clinical trial costs, while SG&A increases were attributed to selling costs and IT infrastructure to support growth. The company maintains a focus on expanding its product offerings and market reach, including the recent FDA approval for a pediatric indication of the G4 PLATINUM system. Liquidity remains a focus, with the company believing its current cash position and access to credit facilities will be sufficient to meet obligations through at least March 31, 2015, though future funding needs may arise.
Financial Highlights
44 data points| Revenue | $46.70M |
| Cost of Revenue | $16.90M |
| Gross Profit | $29.80M |
| R&D Expenses | $14.50M |
| SG&A Expenses | $27.60M |
| Operating Expenses | $42.10M |
| Operating Income | -$12.30M |
| Interest Expense | $200K |
| Net Income | -$12.50M |
| EPS (Basic) | $-0.04 |
| Shares Outstanding (Basic) | 293.20M |
Key Highlights
- 1Product revenues increased significantly by $18.9 million to $46.7 million for the quarter ended March 31, 2014, compared to $27.8 million in the prior year period, primarily due to increased sales volume of the G4 PLATINUM system.
- 2Gross profit increased by $14.4 million to $29.8 million, driven by higher revenues and a greater sales mix of the higher-margin G4 PLATINUM system.
- 3Research and Development (R&D) expenses increased by $5.2 million to $14.5 million, largely due to additional non-cash equity-related expenses, headcount, and clinical trial costs for future product development.
- 4Selling, General, and Administrative (SG&A) expenses increased by $9.5 million to $27.6 million, primarily due to increased headcount-related selling costs and IT infrastructure to support revenue growth and commercialization efforts.
- 5The company received FDA approval for a pediatric indication for the DexCom G4 PLATINUM system on February 3, 2014, expanding its addressable market.
- 6As of March 31, 2014, DexCom had an accumulated deficit of $487.9 million and working capital of $63.9 million, with cash, cash equivalents, and short-term marketable securities totaling $57.4 million.
- 7The company received a warning letter from the FDA on March 14, 2014, related to administrative deficiencies in filing Medical Device Reporting (MDR) procedures, to which it responded on April 2, 2014.